2022
Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV
Gordon KS, Crothers K, Butt AA, Edelman EJ, Gibert C, Pisani MM, Rodriguez-Barradas M, Wyatt C, Justice AC, Akgün KM. Polypharmacy and medical intensive care unit (MICU) admission and 10-year all-cause mortality risk among hospitalized patients with and without HIV. PLOS ONE 2022, 17: e0276769. PMID: 36302039, PMCID: PMC9612570, DOI: 10.1371/journal.pone.0276769.Peer-Reviewed Original ResearchConceptsMedical intensive care unit admissionIntensive care unit admissionCare unit admissionMICU admissionSeverity of illnessHazard ratioHIV statusUnit admissionCause mortalityHospitalized patientsElectronic health record cohortLevel of polypharmacyRetrospective cohort studyCause mortality riskCohort studyHIV infectionCox regressionPolypharmacyMortality riskFiscal year 2009AdmissionPatientsMortalitySubstance useStrong associationAnalysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factorsEpigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus
Oursler KK, Marconi VC, Wang Z, Xu K, Montano M, So-Armah K, Justice AC, Sun YV. Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus. Clinical Infectious Diseases 2022, 76: e638-e644. PMID: 35970820, PMCID: PMC10169393, DOI: 10.1093/cid/ciac656.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusPhysiologic frailtyVACS IndexCause mortalityMortality discriminationImmunodeficiency virusAge accelerationEpigenetic age accelerationVeterans Aging Cohort Study (VACS) IndexWhite blood cell samplesVACS Index 2.0VACS Index scoreNon-Hispanic blacksIntrinsic epigenetic age accelerationExtrinsic epigenetic age accelerationEpigenome-wide DNA methylationBlood cell samplesHazard ratioOne-year increaseCox regressionMean ageC-statisticIndex scoreMortalityStudy indices
2021
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infectionAssociation between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study
Duncan MS, Alcorn CW, Freiberg MS, So-Armah K, Patterson OV, DuVall SL, Crothers KA, Re VL, Butt AA, Lim JK, Kim JW, Tindle HA, Justice AC, Brittain EL. Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. The Lancet Healthy Longevity 2021, 2: e417-e425. PMID: 34296203, PMCID: PMC8294078, DOI: 10.1016/s2666-7568(21)00116-1.Peer-Reviewed Original ResearchConceptsIncident pulmonary hypertensionHIV viral loadPulmonary artery systolic pressureVeterans Aging Cohort StudyPulmonary hypertension riskPulmonary hypertensionRetrospective cohort studyCohort studyViral loadIncidence rateHypertension incidenceCD4 countHazard ratioHIV statusSystolic pressureHypertension riskHigh riskLow CD4 cell countsHepatitis C virus infectionHigher HIV viral loadChronic obstructive pulmonary diseaseCox proportional hazards regressionC virus infectionCD4 cell countPrevalent heart failureStatin exposure and risk of cancer in people with and without HIV infection.
Bedimo RJ, Park LS, Shebl FM, Sigel K, Rentsch CT, Crothers K, Rodriguez-Barradas MC, Goetz MB, Butt AA, Brown ST, Gibert C, Justice AC, Tate JP. Statin exposure and risk of cancer in people with and without HIV infection. AIDS 2021, 35: 325-334. PMID: 33181533, PMCID: PMC7775280, DOI: 10.1097/qad.0000000000002748.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyStatin useStatin exposureHazard ratioCancer riskLower riskPropensity score-matched cohortCox regression hazard ratiosAging Cohort StudyAnti-inflammatory effectsRegression hazard ratiosNon-Hodgkin lymphomaConfidence intervalsCancer registry linkagePropensity score-matched sampleRisk of cancerDeath overallUninfected patientsCohort studyIncident cancerRegistry linkageHIV infectionHIV statusStatin initiatorsUninfected persons
2020
Health System‐Based Unhealthy Alcohol Use Screening and Treatment Comparing Demographically Matched Participants With and Without HIV
Silverberg MJ, Levine‐Hall T, Hood N, Anderson AN, Alexeeff SE, Lam JO, Slome SB, Flamm JA, Hare C, Ross T, Justice A, Sterne JAC, Williams A, Bryant KJ, Weisner CM, Horberg MA, Sterling SA, Satre DD. Health System‐Based Unhealthy Alcohol Use Screening and Treatment Comparing Demographically Matched Participants With and Without HIV. Alcohol Clinical And Experimental Research 2020, 44: 2545-2554. PMID: 33067802, PMCID: PMC7725961, DOI: 10.1111/acer.14481.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useAlcohol use screeningHIV statusBrief interventionRace/ethnicityAlcohol useSpecialty visitsHazard ratioPrevalence ratiosLarge integrated healthcare systemCharlson Comorbidity IndexSpecialty care visitsProportional hazards modelIntegrated healthcare systemOutcomes of timeSubstance use disordersAddiction specialty careNeighborhood deprivation indexElectronic health recordsComorbidity indexAdult PLWHCare visitsCohort studyOutpatient visitsSignificant morbidityFrequency and Duration of Incarceration and Mortality Among US Veterans With and Without HIV.
Hawks LC, McGinnis KA, Howell BA, Khan MR, Edelman EJ, Justice AC, Wang EA. Frequency and Duration of Incarceration and Mortality Among US Veterans With and Without HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 84: 220-227. PMID: 32049771, PMCID: PMC7228828, DOI: 10.1097/qai.0000000000002325.Peer-Reviewed Original ResearchConceptsRisk of mortalityAdjusted hazard ratioCohort studyHIV statusVeterans Aging Cohort StudyCox proportional hazards modelTransitional health careProspective cohort studyAging Cohort StudyConfidence intervalsProportional hazards modelDose-response fashionFrequency of incarcerationDuration of incarcerationIncarceration exposureHIV careHazard ratioPrimary exposureUS veteransLeading causeHigh riskIncrease riskHazards modelCumulative durationPWHPredicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.Peer-Reviewed Original ResearchProstate cancer deathNon-Hispanic blacksNon-Hispanic whitesVeterans Affairs Healthcare SystemRace/ethnicityHazard ratioGleason scoreCancer deathProstate cancerU.S. Veterans Affairs healthcare systemProstate cancer disease progressionDistant metastatic diseaseProstate cancer mortalityCancer disease progressionLocalized diseasePSA levelsMedian ageMetastatic diseaseLymph nodesPrognostic indexCancer mortalityTumor stageDisease progressionCox modelAge strataFIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C
So-Armah KA, Lim JK, Re V, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS, Team V. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress In Cardiovascular Diseases 2020, 63: 184-191. PMID: 32068085, PMCID: PMC7278895, DOI: 10.1016/j.pcad.2020.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsFemaleHealth StatusHeart FailureHepatitis CHIV InfectionsHIV Long-Term SurvivorsHumansIncidenceLiver CirrhosisMaleMiddle AgedPrognosisRisk AssessmentRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsUnited StatesVentricular Function, LeftVeterans HealthViral LoadConceptsType of HFIncident heart failureHeart failureHepatitis C statusAdvanced fibrosisLiver fibrosisEjection fractionHazard ratioC statusVeterans Aging Cohort StudyRisk of HFpEFLast clinic visitReduced ejection fractionAging Cohort StudyLiver fibrosis scoresPrevalent cardiovascular diseaseFirst HF eventProportional hazards modelIncident HFpEFHepatitis CClinic visitsCohort studyPrimary outcomeFibrosis scoreHF eventsDifferences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Re V. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 71-78. PMID: 31575557, PMCID: PMC6980754, DOI: 10.1158/1055-9965.epi-19-0503.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesCarcinoma, HepatocellularFemaleHepatectomyHIV InfectionsHospitals, VeteransHumansImmunologic SurveillanceKaplan-Meier EstimateLiverLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesConceptsBarcelona Clinic Liver Cancer stageHIV statusHepatocellular carcinomaUninfected patientsHIV infectionTumor characteristicsUninfected personsPathology reportsVeterans Aging Cohort StudyLiver tissue samplingCohort of HIVMultivariable Cox regressionAdvanced hepatic fibrosisAging Cohort StudyLiver Cancer stageRisk of deathBackground hepatic parenchymaCohort studyHazard ratioLymphovascular invasionBCLC stageImproved survivalCox regressionHistologic featuresHepatic fibrosis
2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re V. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal Of The National Cancer Institute 2019, 112: 747-755. PMID: 31687755, PMCID: PMC7357318, DOI: 10.1093/jnci/djz214.Peer-Reviewed Original ResearchConceptsRisk of HCCHigher HIV RNAHCC risk factorsHIV RNAHIV viremiaHepatocellular carcinomaBaseline cirrhosisCirrhosis statusCohort studyRisk factorsCell percentageVeterans Aging Cohort StudyDevelopment of HCCCurrent HIV RNADetectable HIV viremiaHepatitis C coinfectionAging Cohort StudyDiagnosis of cirrhosisLonger durationDetectable HIVLow CD4C coinfectionCurrent CD4Hazard ratioCancer Registry
2018
Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV‐Positive and HIV‐Negative Individuals in VACS (Veterans Aging Cohort Study)
Marconi VC, Duncan MS, So‐Armah K, Re VL, Lim JK, Butt AA, Goetz MB, Rodriguez‐Barradas M, Alcorn CW, Lennox J, Beckman JA, Justice A, Freiberg M. Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV‐Positive and HIV‐Negative Individuals in VACS (Veterans Aging Cohort Study). Journal Of The American Heart Association 2018, 7: e007792. PMID: 29720501, PMCID: PMC6015337, DOI: 10.1161/jaha.117.007792.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionTotal cardiovascular diseaseIschemic stroke eventsCardiovascular diseaseCVD eventsHeart failureMyocardial infarctionTotal bilirubinElevated bilirubinStroke eventsRisk factorsIncident total CVDBaseline total bilirubinBaseline cardiovascular diseaseIncident CVD eventsHIV-negative individualsProspective cohort studyElevated bilirubin levelsMultiple risk factorsCohort studyCVD riskHazard ratioIschemic strokeHIV-positiveBilirubin levelsRecent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV
Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 62-72. PMID: 29419568, PMCID: PMC5889316, DOI: 10.1097/qai.0000000000001642.Peer-Reviewed Original ResearchConceptsFramingham risk scoreEffect of abacavirMyocardial infarctionHazard ratioHepatitis C virus infectionType 1Type 2 myocardial infarctionCrude hazard ratioC virus infectionIncident myocardial infarctionInjection drug useHistory of AIDSUse increases riskMarginal structural modelsCohort CollaborationLow CD4Antiretroviral therapyKidney functionMI outcomesTime-dependent confoundingRisk factorsMI occurrenceVirus infectionIncrease riskRisk scoreIncreased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation
Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR, investigators F. Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation. Journal Of The International AIDS Society 2018, 21: e25031. PMID: 29334197, PMCID: PMC5810321, DOI: 10.1002/jia2.25031.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioAntiretroviral therapy initiationAIDS mortalityAdjusted hazardCohort CollaborationTherapy initiationAntiretroviral Therapy Cohort CollaborationHIV-1 infectionTreatment-naïve adultsCause of deathMarginal structural modelsART initiationHIV protocolMetabolic deathHazard ratioChronic inflammationRisk factorsCoding CausesSubsequent deathMortalityAIDSCommon pathwayDeathUnmeasured confoundersCauseCommonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 102-109. PMID: 28991888, PMCID: PMC5720915, DOI: 10.1097/qai.0000000000001562.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS Dementia ComplexAIDS-Related Opportunistic InfectionsAlkynesAmericasAtazanavir SulfateBenzoxazinesCohort StudiesCyclopropanesDarunavirEuropeFemaleHIV Protease InhibitorsHumansLeukoencephalopathy, Progressive MultifocalLopinavirMaleMeningitis, CryptococcalMiddle AgedProspective StudiesReverse Transcriptase InhibitorsToxoplasmosisConceptsNucleoside reverse transcriptase inhibitor (NRTI) backboneReverse transcriptase inhibitor backboneHazard ratioNeurological conditionsInhibitor backbonePooled logistic modelCombined end pointRespective hazard ratiosProgressive multifocal leukoencephalopathyProspective cohort studyAntiretroviral therapy regimensHIV-positive individualsHIV-CAUSAL CollaborationIncidence of AIDSCART initiationHIV dementiaAntiretroviral therapyCART regimenCryptococcal meningitisMultifocal leukoencephalopathyClinical characteristicsCohort studyTherapy regimensAtazanavirLopinavir
2017
Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status
Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Re V. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. Clinical Infectious Diseases 2017, 65: 1542-1550. PMID: 29020184, PMCID: PMC5850026, DOI: 10.1093/cid/cix564.Peer-Reviewed Original ResearchConceptsSevere acute liver injuryAcute liver injuryHuman immunodeficiency virusStatin initiatorsLower riskHCV statusCohort studyHazard ratioStatin nonusersLiver injuryUninfected personsImmunodeficiency virusChronic hepatitis C virus (HCV) infectionHepatitis C virus (HCV) infection statusHIV/HCV-coinfected patientsPropensity score-adjusted hazard ratiosHIV/HCV statusHepatitis C virus infectionVeterans Aging Cohort StudyC virus infectionAging Cohort StudyConfidence intervalsVirus infection statusDevelopment of liverAminotransferase elevationTen-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries
Youn B, Shireman TI, Lee Y, Galárraga O, Rana AI, Justice AC, Wilson IB. Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries. AIDS 2017, 31: 1697-1707. PMID: 28700393, PMCID: PMC5625296, DOI: 10.1097/qad.0000000000001541.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersII receptor blockersHIV patientsControl medicationTherapy persistenceReceptor blockersEnzyme inhibitors/angiotensin II receptor blockersCox proportional hazards modelNon-HIV medicationsUS Medicaid beneficiariesHIV-negative controlsRetrospective cohort studyKaplan-Meier curvesDuration of treatmentProportional hazards modelTen-year trendsSecular trendsART initiatorsCohort studyHazard ratioMedian timeFill dateMedicaid claimsMedicaid beneficiariesAdjusted modelRisk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV-/HCV-coinfected patientsHIV/HCV coinfectionVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injuryCD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4